

Anabela Cordeiro da Silva

Is an Associate Professor of Immunology at the Faculty of Pharmacy of University of Porto (FFUP). Her research group is mostly devoted to understand the cellular and molecular mechanisms occurring during host-parasite interactions.

Started these studies using *Trypanosoma cruzi* during her doctoral work at Pasteur Institute in Paris, and later continued in Porto using *Leishmania* sp and more recently *Trypanosoma brucei* and *Plasmodium*. Has published over 100 original peer reviewed articles, supervised 16 PhD students and many postdocs. Teaches Clinical Immunology for Analytical Analysis at FFUP, University of Porto and participate also on PhD Program on Pharmaceutical Sciences, Programme Medicines and Pharmaceutical Innovation (i3du) and in the Doctoral Programme on Cellular and Molecular Biotechnology Applied to Health Sciences (BiotechHealth). Obtained a First Degree in Pharmaceutical Sciences (1990), Master in Immunology (1992) and a Ph.D. in Biomedical Sciences - Immunology (1997) from University of Porto, Portugal. She has a scientific business graduation from the Business School of Porto that was supported the launch of the start up company, VitaControl. Was born in Viana do Castelo, Portugal, 1966. She is the group leader of Parasite Disease team at the Institute of Molecular Cellular Biology (IBMC) in i3s (Instituto de Investigação e Inovação em Saúde da Universidade do Porto). She was Member of the Scientific Council at FFUP and at IBMC/I3S, was Vice-President of the Education Council of FFUP. She was participated in different evaluation project from FCT, Innovation Agency, IAPEMEI and ANR.

The accumulated know-how of the her group in the parasite host interaction support the participating in a European consortium (HEALTH.2013.2.3.0-1: Innovation in vaccines, MuLeVaClin project) aimed at optimizing and evaluating the potential of a human visceral leishmaniasis vaccine containing recombinant proteins from *Leishmania* and insect salivary glands adjuvanted by a strong TL4 agonist. The group is also heavily involved in drug screening and target validation for novel therapeutical approaches in *Leishmania*, *T. brucei* and *T.*

*cruzi* in the context of two other European consortiums (FP7-HEALTH-2013-INNOVATION-1, Kindred and NMTrypI). For these projects she is involved in several aspects of the preclinical pipeline from early target discovery and validation, advanced toxicology and animal testing and the use of drug delivery systems. A long lasting connection with field diagnostic in Leishmaniasis is harbouring fruits with the ongoing development of a new diagnostic kit. Lastly, the team is starting the implementation of a new biological model using *Plasmodium*. The propose is to dissect how these parasites target the liver by combining live imaging techniques, transgenic parasites and mice. The team also proposes to study the contribution of the liver as a lymphoid organ in the case of sporozoites infection. Ultimately this will contribute to identify potential targets to be considered in vaccine approaches.